

Ingrid Simonitsch-Klupp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4222405/publications.pdf>

Version: 2024-02-01

80
papers

1,828
citations

304743

22
h-index

315739

38
g-index

81
all docs

81
docs citations

81
times ranked

3335
citing authors

#	ARTICLE	IF	CITATIONS
1	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
2	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
3	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2984-2993.	7.0	100
4	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
5	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CTâ€“Controlled Prospective Study in 64 Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2506-2513.	7.0	78
6	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
7	Mutations affecting the actin regulator WD repeatâ€“containing protein 1 lead to aberrant lymphoid immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1589-1604.e11.	2.9	64
8	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. <i>Transplantation</i> , 2021, 105, 451-457.	1.0	57
9	Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. <i>Cell Reports</i> , 2016, 17, 596-608.	6.4	55
10	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 129, 383-385.	1.4	51
11	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	4.5	49
12	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	3.2	49
13	Preâ€“fibrotic/early primary myelofibrosis vs. WHOâ€“defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <i>American Journal of Hematology</i> , 2017, 92, 885-891.	4.1	47
14	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	1.4	45
15	Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. <i>Oncotarget</i> , 2017, 8, 16463-16472.	1.8	43
16	Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis. <i>Cancer Discovery</i> , 2019, 9, 1406-1421.	9.4	42
17	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	7.2	40
18	Mutations outside the N-terminal part of RBCK1 may cause polyglucosan body myopathy with immunological dysfunction: expanding the genotypeâ€“phenotype spectrum. <i>Journal of Neurology</i> , 2018, 265, 394-401.	3.6	36

#	ARTICLE	IF	CITATIONS
19	Neuropathological Variability within a Spectrum of ^{NMDAR} Encephalitis. <i>Annals of Neurology</i> , 2021, 90, 725-737.	5.3	35
20	NF- κ B contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier <i>in vitro</i> . <i>Oncotarget</i> , 2015, 6, 39262-39275.	1.8	30
21	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. <i>Blood Advances</i> , 2017, 1, 352-356.	5.2	29
22	Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 666935.	4.8	27
23	CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸ Ga]Pentixafor: comparison with [¹⁸ F]FDG-PET. <i>Theranostics</i> , 2021, 11, 567-578.	10.0	26
24	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <i>Molecular Cancer Research</i> , 2017, 15, 541-552.	3.4	24
25	Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 931-940.	6.4	23
26	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line <i>Helicobacter</i> eradication. <i>Blood</i> , 2022, 139, 240-244.	1.4	22
27	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	3.5	21
28	Super-enhancer-based identification of a BATF3/IL-2R γ module reveals vulnerabilities in anaplastic large cell lymphoma. <i>Nature Communications</i> , 2021, 12, 5577.	12.8	21
29	Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. <i>Hematological Oncology</i> , 2019, 37, 22-26.	1.7	20
30	12(S)-HETE increases intracellular Ca ²⁺ in lymph-endothelial cells disrupting their barrier function <i>in vitro</i> ; stabilization by clinical drugs impairing calcium supply. <i>Cancer Letters</i> , 2016, 380, 174-183.	7.2	18
31	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. <i>European Journal of Cancer</i> , 2016, 64, 159-166.	2.8	16
32	Correlation between glycolytic activity on [18F]FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1217-1226.	3.4	16
33	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. <i>British Journal of Haematology</i> , 2019, 186, 448-459.	2.5	16
34	Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Oncologist</i> , 2016, 21, 72-75.	3.7	15
35	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. <i>Cancers</i> , 2020, 12, 9.	3.7	15
36	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories. <i>Cancer Medicine</i> , 2019, 8, 4656-4668.	2.8	14

#	ARTICLE	IF	CITATIONS
37	Functional characterization, localization, and inhibitor sensitivity of the <sc>TPR</sc>FCFR1 fusion in 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 60-68.	2.8	13
38	Bone Marrow Involvement in Malignant Lymphoma. <i>Academic Radiology</i> , 2018, 25, 453-460.	2.5	13
39	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2016, 57, 206-208.	1.3	12
40	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2018, 36, 49-55.	1.7	12
41	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Hematological Oncology</i> , 2018, 36, 62-67.	1.7	12
42	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 251-258.	2.2	12
43	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. <i>Blood Cancer Journal</i> , 2017, 7, 643.	6.2	11
44	Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) – Real-world data from the Medical University of Vienna. <i>Hematological Oncology</i> , 2019, 37, 345-351.	1.7	11
45	Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. <i>Molecular Imaging and Biology</i> , 2019, 21, 1192-1199.	2.6	11
46	Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging. <i>PLoS ONE</i> , 2016, 11, e0164118.	2.5	10
47	The WHO diagnostic criteria for polycythemia vera – role of red cell mass versus hemoglobin/hematocrit level and morphology. <i>Annals of Hematology</i> , 2018, 97, 1581-1590.	1.8	10
48	Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease – A 20-years' experience from Austria. <i>Cancer Reports</i> , 2021, 4, e1375.	1.4	10
49	Impaired efferocytosis by monocytes in multiple myeloma. <i>Oncology Letters</i> , 2018, 16, 409-416.	1.8	9
50	Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients. <i>Digestive Diseases</i> , 2019, 37, 194-200.	1.9	9
51	Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2021, 13, 2993.	3.7	9
52	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1662-1662.	1.4	9
53	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9
54	Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. <i>Annals of Hematology</i> , 2016, 95, 1115-1120.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 3232-3235.	3.5	8
56	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Cancers</i> , 2020, 12, 492.	3.7	7
57	Management of children and adolescents with gray zone lymphoma: A case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28206.	1.5	7
58	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
59	The cancer survival indexâ€”A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
60	Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2017, 35, 177-186.	1.7	6
61	Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29285.	1.5	6
62	Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum. <i>Case Reports in Oncology</i> , 2018, 11, 239-245.	0.7	4
63	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. <i>Annals of Hematology</i> , 2020, 99, 2599-2609.	1.8	4
64	First Line Systemic Treatment for MALT Lymphomaâ€”Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. <i>Cancers</i> , 2020, 12, 3533.	3.7	4
65	Concurrent Acute Myelofibrosis and Acute Lymphoblastic Leukemia in Childhood: Case Report and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 235-237.	0.6	3
66	Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. <i>Cancers</i> , 2020, 12, 2291.	3.7	3
67	Difficulties in the differential diagnosis of large solitary pulmonary cysts. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 1157-1159.	1.1	3
68	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. <i>Blood</i> , 2016, 128, 4252-4252.	1.4	2
69	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 123-126.	0.5	1
70	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
71	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. <i>Blood</i> , 2019, 134, 4037-4037.	1.4	1
72	Chondroid hamartoma of the lung presenting as cavern. <i>Clinical Respiratory Journal</i> , 2016, 10, 671-672.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Recalcitrant rash in a six-month-old infant. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1254-1257.	0.8	0
74	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?. Journal of Hematopathology, 2021, 14, 325-332.	0.4	0
75	Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.. Blood, 2004, 104, 3459-3459.	1.4	0
76	Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria. Blood, 2015, 126, 2816-2816.	1.4	0
77	Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis. Blood, 2016, 128, 1932-1932.	1.4	0
78	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	1.4	0
79	Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication. Blood, 2018, 132, 3043-3043.	1.4	0
80	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. Blood, 2020, 136, 26-26.	1.4	0